Six-Month Injection Shows Promising Results as New HIV Prevention Method
A new HIV prevention method, delivered via a six-month injection, has demonstrated remarkable effectiveness in clinical trials. Lenacapavir, the long-acting antiretroviral drug, proved to be significantly more effective than daily oral PrEP (pre-exposure prophylaxis), according to research published in the esteemed New England Journal of Medicine.
The international study, led by researchers from Emory University and Grady Health System, involved over 2,000 participants. Only two individuals receiving Lenacapavir contracted HIV, compared to nine cases among those taking daily PrEP. This translates to an overall effectiveness rate of 96% for Lenacapavir, highlighting its potential as a game-changer in HIV prevention.
“Lenacapavir’s near 100% effectiveness is remarkable, especially for those who cannot take the drug every day or who have limited medical resources,” said Dr. Colleen Kelley, professor at Emory University School of Medicine and the study’s lead investigator.
The trial enlisted diverse participants from countries including Peru, Brazil, Argentina, Mexico, South Africa, Thailand, and the United States, deliberately targeting communities disproportionately impacted by HIV. This focus stemmed from the recognition that many individuals in these groups struggle with adhering to daily medication regimens, underscoring the urgent need for more convenient and accessible alternatives.
The alarming statistic that over half of new HIV cases in the United States in 2022 were among cisgender gay men, with 70% being African-American or Hispanic, further emphasizes the critical need for flexible prevention strategies.
With the successful completion of the Phase III clinical trial, marke
ting applications for Lenacapavir have been submitted to the U.S. Food and Drug Administration. Researchers are hopeful for approval by 2025, potentially offering a groundbreaking solution for individuals who face challenges with traditional daily medication.
Dr. Carlos del Rio, head of the Department of Internal Medicine at Emory University, highlighted the significance of this breakthrough: “Long-acting antiretroviral drugs add new tools to HIV prevention. HIV infections worldwide Increase the number of HIV infection.”
Lenacapavir’s impressive effectiveness, coupled with its convenient administration, holds immense promise for reducing HIV transmission rates and transforming HIV prevention efforts globally.
An HIV prevention injection (Lenacapavir) is given every six months, and clinical trials have shown it to be more effective than oral PrEP. (Associated Press)
2024-12-01 05:14:00
#day #AIDS #prevention #injections #effective #year #Free #Health #Network
## Six-Month HIV Prevention Injection: A Game Changer in the fight Against AIDS?
**New research has unveiled a promising new weapon in the battle against HIV – a long-acting injection offering near 100% effectiveness.** This breakthrough method, utilizing the drug Lenacapavir, outperforms daily oral prep (pre-exposure prophylaxis) and could revolutionize HIV prevention strategies globally.
To delve deeper into this exciting advancement, we’ve invited two leading experts: **Dr. Colleen Kelley**, professor at Emory University School of Medicine and lead investigator of the groundbreaking Lenacapavir trial, and **Dr. Carlos del Rio**, head of the Department of Internal Medicine at Emory University, renowned for his work in HIV/AIDS treatment and prevention.
**the Science Behind Lenacapavir’s Success**
***
**World Today News editor:** Dr. Kelley, your study demonstrated remarkable results for Lenacapavir. Can you explain how this long-acting injection works and what makes it so effective?
**Dr. Colleen Kelley:** Lenacapavir is a novel, long-acting HIV capsid inhibitor. It effectively works by binding to the HIV capsid protein,preventing the virus from replicating within cells. The beauty of this approach is its duration. A single injection provides protection for six months, eliminating the need for daily pills and significantly improving adherence.
**World Today News Editor:** Dr. del Rio, considering the persistent challenges of HIV transmission worldwide, how important is this breakthrough in your opinion?
**Dr. Carlos del Rio:** This is a monumental advancement.Lenacapavir’s effectiveness and convenience offer a powerful new tool in our arsenal against HIV. It addresses a crucial need for more flexible and accessible prevention options, especially for individuals who face barriers to daily medication.
**Targeting high-Risk Communities and Addressing Health Disparities**
***
**World Today News Editor:** Dr. Kelley,the trial specifically focused on diverse populations disproportionately affected by HIV. Why was this a priority?
**Dr. Colleen kelley:** We know that marginalized communities, particularly men who have sex with men, transgender individuals, and People of Color often face systemic barriers to healthcare access and struggle with adherence to daily medication regimens.
**World Today News Editor:** Dr. del Rio, how can this injection contribute to addressing these health disparities?
**Dr. Carlos del Rio:**
*”Lenacapavir can be a game-changer, offering discreet and convenient protection for those who may find daily medication challenging.”* **
It has the potential to significantly reduce new HIV infections within these vulnerable populations, contributing to a more equitable and healthier society.
**Outlook for the Future: approval and Impact**
***
**World Today News Editor:** Dr. Kelley, what are the next steps following the successful Phase III trial?
**Dr. Colleen Kelley:** We have submitted marketing applications to the U.S. Food and Drug Management, and we are hopeful for approval by 2025.
**World today News Editor:** Dr.del Rio, how do you envision Lenacapavir impacting the future of HIV prevention globally?
**Dr. Carlos del Rio:** I believe Lenacapavir represents a significant leap forward in HIV prevention.
*”Its success paves the way for the development of other long-acting antiretroviral drugs,promising a future where individuals have more choices and control over their sexual health.”*
** Key Takeaways:**
Lenacapavir’s six-month injection format and remarkable effectiveness offer a transformative alternative to daily PrEP, holding immense promise for reducing HIV transmission rates and shifting the trajectory of the HIV/AIDS pandemic.
**Join the Conversation:**
Share your thoughts on this exciting development in HIV prevention. Could this new method be the breakthrough we need? Let us know in the comments below.
**Learn More:**
Read our related articles on HIV/AIDS prevention, treatment advancements, and global health initiatives.
